MedTrace Logo

Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

NCT01375699 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-08-26

No results posted yet for this study

Summary

Sildenafil increases the therapeutic effect of doxorubicin used as treatment for cancers of solid tumors through both an increase in anti-tumor effects and protection from cardiac toxicity.

Conditions

Interventions

DRUG

Doxorubicin

As prescribed by treating provider.

DRUG

Sildenafil

Given PO, by mouth

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Andrew S. Poklepovic, MD · Massey Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-11
Primary Completion
2017-08-04
Completion
2018-01-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01375699 on ClinicalTrials.gov